Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells

Molecular Oncology

Volumn 6, Issue 5, 2012, Pages 484-493

  Nam, Sangkil ^a   Xie, Jun ^a   Perkins, Angela ^a   Ma, Yuelong ^a   Yang, Fan ^a   Wu, Jun ^a   Wang, Yan ^a   Xu, Rong zhen ^b   Huang, Wendong ^a   Horne, David A ^a   Jove, Richard ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Berbamine derivatives (BBMDs); Jak2; Stat3

Indexed keywords

BERBAMINE; JANUS KINASE 2; PROTEIN BCL XL; PROTEIN MCL 1; STAT2 PROTEIN; TYROSINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; MELANOMA; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

BERBERIS AMURENSIS;

EID: 84866022781     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.05.002     Document Type: Article

References (44)

1. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
2. Bill M.A., Fuchs J.R., Li C., Yui J., Bakan C., Benson D.M., Schwartz E.B., Abdelhamid D., Lin J., Hoyt D.G., Fossey S.L., Young G.S., Carson W.E., Li P.K., Lesinski G.B. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol. Cancer 2010, 9:165.
3. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63:1270-1279.
4. Boisvert-Adamo K., Longmate W., Abel E.V., Aplin A.E. Mcl-1 is required for melanoma cell resistance to anoikis. Mol. Cancer Res. 2009, 7:549-556.
5. Brantley E.C., Benveniste E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol. Cancer Res. 2008, 6:675-684.
6. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
7. Campbell G.S., Yu C.L., Jove R., Carter-Su C. Constitutive activation of JAK1 in Src-transformed cells. J. Biol. Chem. 1997, 272:2591-2594.
8. Cummins D.L., Cummins J.M., Pantle H., Silverman M.A., Leonard A.L., Chanmugam A. Cutaneous malignant melanoma. Mayo Clin. Proc. 2006, 81:500-507.
9. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
10. De Nicolo A., Parisini E., Zhong Q., Dalla Palma M., Stoeckert K.A., Domchek S.M., Nathanson K.L., Caligo M.A., Vidal M., Cusick M.E., Garber J.E. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. Cancer Res. 2009, 69:7030-7037.
11. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J.M., Yang-Yen H.F., Karras J., Jove R., Loughran T.P. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 2001, 107:351-362.
12. Feng J., Witthuhn B.A., Matsuda T., Kohlhuber F., Kerr I.M., Ihle J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell Biol. 1997, 17:2497-2501.
13. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A., Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
14. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
15. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z.A., Yu H., Jove R., Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
16. Kong L.Y., Abou-Ghazal M.K., Wei J., Chakraborty A., Sun W., Qiao W., Fuller G.N., Fokt I., Grimm E.A., Schmittling R.J., Archer G.E., Sampson J.H., Priebe W., Heimberger A.B. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin. Cancer Res. 2008, 14:5759-5768.
17. Kortylewski M., Jove R., Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 2005, 24:315-327.
18. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
19. Leonard W.J., O'Shea J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 1998, 16:293-322.
20. Levine R.L., Gilliland D.G. Myeloproliferative disorders. Blood 2008, 112:2190-2198.
21. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
22. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
23. Liang Y., Xu R.Z., Zhang L., Zhao X.Y. Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta Pharmacol. Sin. 2009, 30:1659-1665.
24. Liu L., Nam S., Tian Y., Yang F., Wu J., Wang Y., Scuto A., Polychronopoulos P., Magiatis P., Skaltsounis L., Jove R. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 2011, 71:3972-3979.
25. Luo C., Laaja P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov. Today 2004, 9:268-275.
26. Nagata M., Wada K., Nakajima A., Nakajima N., Kusayama M., Masuda T., Iida S., Okura M., Kogo M., Kamisaki Y. Role of myeloid cell leukemia-1 in cell growth of squamous cell carcinoma. J. Pharmacol. Sci. 2009, 110:344-353.
27. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., Hippe F., Vatter S., Merz K.H., Eisenbrand G., Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. U S A 2005, 102:5998-6003.
28. Nam S., Kim D., Cheng J.Q., Zhang S., Lee J.H., Buettner R., Mirosevich J., Lee F.Y., Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005, 65:9185-9189.
29. Niu G., Bowman T., Huang M., Shivers S., Reintgen D., Daud A., Chang A., Kraker A., Jove R., Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21:7001-7010.
30. O'Shea J.J., Gadina M., Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109(Suppl.):S121-S131.
31. O'Shea J.J., Pesu M., Borie D.C., Changelian P.S. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 2004, 3:555-564.
32. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
33. Rane S.G., Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19:5662-5679.
34. Rane S.G., Reddy E.P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002, 21:3334-3358.
35. Reddy E.P., Korapati A., Chaturvedi P., Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 2000, 19:2532-2547.
36. Samanta A.K., Chakraborty S.N., Wang Y., Kantarjian H., Sun X., Hood J., Perrotti D., Arlinghaus R.B. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009, 28:1669-1681.
37. Sen B., Saigal B., Parikh N., Gallick G., Johnson F.M. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 2009, 69:1958-1965.
38. Wang S., Liu Q., Zhang Y., Liu K., Yu P., Luan J., Duan H., Lu Z., Wang F., Wu E., Yagasaki K., Zhang G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol. Cancer 2009, 8:81.
39. Wei Y.L., Xu L., Liang Y., Xu X.H., Zhao X.Y. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacol. Sin. 2009, 30:451-457.
40. Xie J., Ma T., Gu Y., Zhang X., Qiu X., Zhang L., Xu R., Yu Y. Berbamine derivatives: a novel class of compounds for anti-leukemia activity. Eur. J. Med. Chem. 2009, 44:3293-3298.
41. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
42. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
43. Zhang Y., Turkson J., Carter-Su C., Smithgall T., Levitzki A., Kraker A., Krolewski J.J., Medveczky P., Jove R. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem. 2000, 275:24935-24944.
44. Zhang H., Guttikonda S., Roberts L., Uziel T., Semizarov D., Elmore S.W., Leverson J.D., Lam L.T. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011, 30:1963-1968.